HHS Touts MMA Drug Provisions As Counterweight To High Medicare Costs
This article was originally published in The Pink Sheet Daily
Executive Summary
E-prescribing, medication therapy management, the availability of generics through Part D, and a focus on drug effectiveness data will bolster Medicare’s fiscal integrity, HHS says. The 2005 Medicare Trustees Report projects that the hospital insurance trust fund will be insolvent in 2020.
You may also be interested in...
CMS Projects Annual Medicare Rx Market Of $181 Bil. In 2015
The agency projects that total payments to Medicare Rx plans over fiscal years 2006-2015 will be $1.2 tril. CMS stresses that the new cost projections are consistent with previous estimates, plus two additional years of the drug benefit in action.
Endo’s Lidoderm Mailings Draw FDA Warning Letter For Unsubstantiated Claims
FDA asks Endo to disseminate “corrective messages” to doctors who received the violative promotional materials, which the agency says omit risk information and contain unsubstantiated effectiveness claims.
Efficacy Differences Within Drug Classes Unsupported By Data, FDA's Temple Says
Studies that look for differences in efficacy among members of the same drug class are only performed when necessary for approval, CDER Office of Medical Policy Director Temple tells DIA. While questioning the introduction of "follow-on" compounds, Temple also highlights AstraZeneca's success in achieving a more optimal dose for Nexium.